Deferoxamine for patients with advanced pancreatic cancer: pilot study

Deferoxamine for patients with advanced pancreatic cancer: pilot study - DFO for pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009054

Enrollment

Registered

2012-10-09

Start date

2012-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Administration of Deferoxamine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Advanced pancreatic cancer diagnosed based on the histological findings (StageIVa<=) 2)Standard treatment-resistant patients (GEM and/or TS-1) 3)Patients who have no influence on previous treatment 4) Performance status (PS) 0 or 1 5) Favorable function of major organ (bone marrow, kidny, heart), and meeting criteria as fellows: (1) neutrophil >= 1500/mm3 (2) platelet count>= 50000/mm3 (3) hemogrobin level >= 8.5g/dl (4) serum creatinine level < 2mg/dl 6) age >= 20years, male and female

Exclusion criteria

Exclusion criteria: 1) Severe coexisting illness 2) Active bouble cancers 3) serum creatinine level >= 2mg/dl 4) Past history of hypersensitivity for drugs including iodine and contrast agent 5) Patients with pregnancy, lactation or possibility of pregnancy 6) Patients who judged as inadequacy due to other reasons by the doctor

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Overall survival, progression-free survival, anti-tumor effect	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026